Evidence map›Paper›PMID 37937980›Full record

ReviewClinical microbiology reviews2023

Human strongyloidiasis: complexities and pathways forward.

Dora Buonfrate, Richard S Bradbury, Matthew R Watts, Zeno Bisoffi

Abstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. IvermectinParasitology · 2024
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Words and Worms: The Nosology of Strongyloidiasis.The American journal of tropical medicine and hygiene · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Taxonomy ofParasitology · 2026
    Review
  14. Article
  15. Article
  16. Clinical Insights intoInfection and drug resistance · 2026
    Article
  17. Review
  18. Article
  19. Discovery of Polyphenolic Compounds fromCurrent computer-aided drug design · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dora Buonfrate *Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.ORCID 0000-0003-0108-6822
Richard S Bradbury *School of Health and Life Sciences, Federation University Australia, Berwick, Victoria, Australia.ORCID 0000-0002-5524-506X
Matthew R Watts *Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research - New South Wales Health Pathology and Sydney Institute for Infectious Diseases, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.ORCID 0009-0009-5219-2976
Zeno Bisoffi *Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.ORCID 0000-0001-9530-8742

Funding

Italian Ministry of Health Ricerca corrente, L3P1
6 · The paper itself

Abstract

Strongyloidiasis is a World Health Organization neglected tropical disease usually caused by

Indexed as

Strongyloides stercoralisStrongyloidiasisAnimalsChildHumansImmunocompromised HostImmunosuppression TherapyIvermectinIvermectinneglected tropical diseasessoil-transmitted helminthStrongyloidesstrongyloidiasis

Identifiers

PMID37937980
PMCPMC10732074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.